Aurobindo Pharma subsidiary enters pact with BioFactura for biosimilar ustekinumab

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma said it has entered into an exclusive license agreement with the US-based BioFactura to commercialize BFI-751, a proposed biosimilar to Stelara (ustekinumab).

Ustekinumab is used for treating Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

As part of the agreement BioFactura will receive license fees of a total not exceeding $33.5 million spread across different milestones leading to commercialization in regulated markets.


A profit-sharing arrangement has been agreed by both the parties with CuraTeQ receiving 57 - 60% of the profits depending upon the markets.

CuraTeQ will have global manufacturing rights for the Ustekinumab biosimilar.